Back to Journals » Biologics: Targets and Therapy » Volume 12
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Two decades with omalizumab: what we still have to learn
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
19,445 | Dovepress* | 14,889+ | 1,537 | 16,426 | |
PubMed Central* | 4,556 | 892 | 5,448 | ||
Totals | 19,445 | 2,429 | 21,874 | ||
*Since 26 October 2018 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
8 | 0 | 0 | 0 | 3 | 5 |
View citations on PubMed Central and Google Scholar